Market Overview

Oragenics, Intrexon Announce Deal to Develop Genetically Modified Probiotics, Intrexon Invests $3.9M in Oragenics

Related XON
ZIOPHARM Announces Expansion Of Ground-Breaking Synthetic Immuno-Oncology Programs With Intrexon And Clinical Program Update
Intrexon To Acquire Trans Ova Genetics

Oragenics, Inc. (NYSE: OGEN), a leader in the development of novel, effective antibiotics and oral care probiotics, and Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced the establishment of an Exclusive Channel Collaboration (ECC) to develop and commercialize genetically modified probiotics for the treatment of diseases of the oral cavity, throat, sinus and esophagus. The team is expected to initially focus on therapies for Behcet's disease and aphthous stomatitis.

The collaborators will utilize their technical and clinical expertise with genetically modified oral microbes to pursue a novel, short-term therapeutic agent.  The ECC plans to design genetically modified probiotics that will work orally, administered in, for example, lozenge form rather than through the digestive system – thereby increasing the probability of effective treatment outcomes.

It is anticipated that the therapeutic will treat oral lesions associated with Behcet's, targeting pain management and functional impairment by suppressing the inflammatory response, reducing frequency of occurrence and avoiding the onset of new lesions. The same treatment may also be applicable in the more commonly experienced recurrent aphthuous stomatitis, better known as canker sores. Both disease states are currently only treated symptomatically and with limited success.

Posted-In: News Contracts

 

Most Popular

Related Articles (XON + OGEN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters